Macular Degeneration Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Macular Degeneration Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

The global macular degeneration treatment market size reached US$ 8.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 12.9 Billion by 2028, exhibiting a growth rate (CAGR) of 6.2% during 2023-2028.

Macular degeneration is a neurodegenerative ocular disorder that affects the eyes and causes blurred or loss of vision in the center of the visual field. It is characterized by blind spots in the field of vision, visual distortions and inability to see in low light conditions. Some of the commonly used therapeutic techniques for macular degeneration includes anti-angiogenic drugs, photodynamic laser therapies, contact lenses and transitional lenses. Laser therapy involves the insertion of specialized contact lenses into the affected are of the eye, which are sealed by lasers along with the blood vessels. Anti-angiogenic drugs are used for preventing blockages and leakages in the blood vessels. Timely treatment of macular degeneration treatment can aid in enhancing vision and minimizing the risks of developing chronic blindness.

Macular Degeneration Treatment Market Trends:
The increasing incidences of age-related macular degeneration and obesity among the masses is one of the key factors driving the market growth. The changing dietary patterns and the rising adoption of sedentary lifestyles is leading to the development of macular degeneration. Additionally, the increasing utilization of smartphones, laptops and television, which is leading to prolonged and excessive screen time is also impacting the occurrence of the disorder. Moreover, the development of retinal gene therapies that involves the injection of adeno-associated virus (AAV) into the body for preventing the development of abnormal blood vessels is providing a thrust to the market growth. In line with this, significant improvements in the healthcare infrastructure is positively impacting the market growth. Other factors, including extensive research and development (R&D) activities for the development of innovative and effective drugs, along with the implementation of various government initiatives for promoting public health, are anticipated to drive the market toward growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global macular degeneration treatment market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, stage of disease, route of administration and end user.

Breakup by Type:

Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration

Breakup by Stage of Disease:

Early Stage
Intermediate Stage
Late Stage

Breakup by Route of Administration:

Intravenous Route
Intravitreal Route

Breakup by End User:

Hospitals
Ambulatory Surgical Center
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Iveric Bio Inc., Novartis AG, Panoptica, Pfizer Inc., Phio Pharmaceuticals, Regeneron Pharmaceuticals Inc., Regenxbio Inc. and Santen Pharmaceutical Co. Ltd.

Key Questions Answered in This Report

1. What was the size of the global macular degeneration treatment market in 2022?
2. What is the expected growth rate of the global macular degeneration treatment market during 2023-2028?
3. What are the key factors driving the global macular degeneration treatment market?
4. What has been the impact of COVID-19 on the global macular degeneration treatment market?
5. What is the breakup of the global macular degeneration treatment market based on the type?
6. What is the breakup of the global macular degeneration treatment market based on the stage of disease?
7. What is the breakup of the global macular degeneration treatment market based on the route of administration?
8. What is the breakup of the global macular degeneration treatment market based on the end user?
9. What are the key regions in the global macular degeneration treatment market?
10. Who are the key players/companies in the global macular degeneration treatment market?


1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Macular Degeneration Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Dry Age-related Macular Degeneration
  6.1.1 Market Trends
  6.1.2 Market Forecast
6.2 Wet Age-related Macular Degeneration
  6.2.1 Market Trends
  6.2.2 Market Forecast
7 Market Breakup by Stage of Disease
7.1 Early Stage 
  7.1.1 Market Trends
  7.1.2 Market Forecast
7.2 Intermediate Stage 
  7.2.1 Market Trends
  7.2.2 Market Forecast
7.3 Late Stage 
  7.3.1 Market Trends
  7.3.2 Market Forecast
8 Market Breakup by Route of Administration
8.1 Intravenous Route
  8.1.1 Market Trends
  8.1.2 Market Forecast
8.2 Intravitreal Route
  8.2.1 Market Trends
  8.2.2 Market Forecast
9 Market Breakup by End User
9.1 Hospitals
  9.1.1 Market Trends
  9.1.2 Market Forecast
9.2 Ambulatory Surgical Center
  9.2.1 Market Trends
  9.2.2 Market Forecast
9.3 Others
  9.3.1 Market Trends
  9.3.2 Market Forecast
10  Market Breakup by Region
10.1 North America
  10.1.1 United States
   10.1.1.1 Market Trends
   10.1.1.2 Market Forecast
  10.1.2 Canada
   10.1.2.1 Market Trends
   10.1.2.2 Market Forecast
10.2 Asia-Pacific
  10.2.1 China
   10.2.1.1 Market Trends
   10.2.1.2 Market Forecast
  10.2.2 Japan
   10.2.2.1 Market Trends
   10.2.2.2 Market Forecast
  10.2.3 India
   10.2.3.1 Market Trends
   10.2.3.2 Market Forecast
  10.2.4 South Korea
   10.2.4.1 Market Trends
   10.2.4.2 Market Forecast
  10.2.5 Australia
   10.2.5.1 Market Trends
   10.2.5.2 Market Forecast
  10.2.6 Indonesia
   10.2.6.1 Market Trends
   10.2.6.2 Market Forecast
  10.2.7 Others
   10.2.7.1 Market Trends
   10.2.7.2 Market Forecast
10.3 Europe
  10.3.1 Germany
   10.3.1.1 Market Trends
   10.3.1.2 Market Forecast
  10.3.2 France
   10.3.2.1 Market Trends
   10.3.2.2 Market Forecast
  10.3.3 United Kingdom
   10.3.3.1 Market Trends
   10.3.3.2 Market Forecast
  10.3.4 Italy
   10.3.4.1 Market Trends
   10.3.4.2 Market Forecast
  10.3.5 Spain
   10.3.5.1 Market Trends
   10.3.5.2 Market Forecast
  10.3.6 Russia
   10.3.6.1 Market Trends
   10.3.6.2 Market Forecast
  10.3.7 Others
   10.3.7.1 Market Trends
   10.3.7.2 Market Forecast
10.4 Latin America
  10.4.1 Brazil
   10.4.1.1 Market Trends
   10.4.1.2 Market Forecast
  10.4.2 Mexico
   10.4.2.1 Market Trends
   10.4.2.2 Market Forecast
  10.4.3 Others
   10.4.3.1 Market Trends
   10.4.3.2 Market Forecast
10.5 Middle East and Africa
  10.5.1 Market Trends
  10.5.2 Market Breakup by Country
  10.5.3 Market Forecast
11  SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12  Value Chain Analysis
13  Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14  Price Analysis
15  Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
  15.3.1 Aerie Pharmaceuticals Inc.
   15.3.1.1 Company Overview
   15.3.1.2 Product Portfolio
   15.3.1.3 Financials
  15.3.2 Bausch Health Companies Inc.
   15.3.2.1 Company Overview
   15.3.2.2 Product Portfolio
   15.3.2.3 Financials
   15.3.2.4 SWOT Analysis
  15.3.3 Bayer AG
   15.3.3.1 Company Overview
   15.3.3.2 Product Portfolio
   15.3.3.3 Financials
   15.3.3.4 SWOT Analysis
  15.3.4 F. Hoffmann-La Roche Ltd
   15.3.4.1 Company Overview
   15.3.4.2 Product Portfolio
   15.3.4.3 Financials
  15.3.5 Iveric Bio Inc.
   15.3.5.1 Company Overview
   15.3.5.2 Product Portfolio
   15.3.5.3 Financials
  15.3.6 Novartis AG
   15.3.6.1 Company Overview
   15.3.6.2 Product Portfolio
   15.3.6.3 Financials
   15.3.6.4 SWOT Analysis
  15.3.7 Panoptica
   15.3.7.1 Company Overview
   15.3.7.2 Product Portfolio
  15.3.8 Pfizer Inc.
   15.3.8.1 Company Overview
   15.3.8.2 Product Portfolio
   15.3.8.3 Financials
   15.3.8.4 SWOT Analysis
  15.3.9 Phio Pharmaceuticals
   15.3.9.1 Company Overview
   15.3.9.2 Product Portfolio
   15.3.9.3 Financials
  15.3.10 Regeneron Pharmaceuticals Inc.
   15.3.10.1 Company Overview
   15.3.10.2 Product Portfolio
   15.3.10.3 Financials
   15.3.10.4 SWOT Analysis
  15.3.11 Regenxbio Inc.
   15.3.11.1 Company Overview
   15.3.11.2 Product Portfolio
   15.3.11.3 Financials
   15.3.11.4 SWOT Analysis
  15.3.12 Santen Pharmaceutical Co. Ltd.
   15.3.12.1 Company Overview
   15.3.12.2 Product Portfolio
   15.3.12.3 Financials
   15.3.12.4 SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings